

25 β_2 -glycoprotein I and Anti- β_2 -glycoprotein I Antibodies

Shinsuke Yasuda, Tatsuya Atsumi, and Takao Koike

Introduction

In patients with antiphospholipid syndrome (APS), pathogenic antiphospholipid antibodies (aPL) are not directed against phospholipids itself, but against plasma proteins that bind to negatively charged surface, such as β_2 -glycoprotein-I (β_2 -GPI) [1–3], prothrombin [4–6], annexin V, protein C, protein S, high- and low-molecular-weight kininogens [7], tissue plasminogen activator [8], factor VII [9], factor XII [10], complement component C4, and complement factor H [11]. Among them, autoantibodies against β_2 -GPI have been extensively investigated and recognized as the most relevant, because anti- β_2 -GPI autoantibodies are not only a marker of APS [12], but also seem to play pathogenic roles in developing thrombosis [12, 13].

Structure and Physiological Function of β_2 -GPI

β_2 -GPI, also known as apolipoprotein H, is a 50-kDa phospholipid binding protein present in plasma at an approximate concentration of 200 $\mu\text{g/mL}$. β_2 -GPI has 5 homologous short consensus repeats and 4 glycation sites, forming an elongated fishhook-like 3-dimensional structure. Domains of β_2 -GPI structurally resemble each other, except that domain V has an extra C-terminal loop and a positively charged lysine cluster. According to the crystal structure of human β_2 -GPI, it was proposed that this large positively charged patch interacts with negatively charged phospholipid with a flexible and partially hydrophobic loop inserted into the lipid layer when it binds to the cell surface [14, 15] (Fig. 25.1). β_2 -GPI also binds to other negatively charged molecules such as heparin, DNA, oxidized low-density lipoprotein (LDL) [16, 17], and apoptotic bodies [18].

Because negatively charged molecules trigger the intrinsic coagulation pathway, β_2 -GPI was proposed to be a natural anticoagulant. β_2 -GPI inhibits prothrombinase and tenase activity on platelets or phospholipid vesicles [19], inhibits factor XII activation [20], and modulates ADP-dependent activation of platelets [21]. Recently, β_2 -GPI has been shown to bind directly to factor XI and attenuate its activation [22]. On the other hand, β_2 -GPI exerts procoagulant activities by reduction of activated protein C [23]. Data from knockout mice suggests that β_2 -GPI may




Figure 25.1. Structure of human β_2 -GPI and binding model of β_2 -GPI and phospholipids. (A) Two views, related by 180° rotation of the electrostatic potential surface of β_2 -GPI. (B) Positively charged patch on the aberrant half of domain V. (C) Diagram of the proposed model for binding of β_2 -GPI to anionic phospholipids. [Reprinted from Bouma et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999;18:5171.]